September 24, 2018 / 5:39 AM / a month ago

Roche deepens push into personalised cancer care with new test

ZURICH, Sept 24 (Reuters) - Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common cancer gene mutations from a patient’s blood.

The blood test, called FoundationOne Liquid, is among the first products to emerge from Foundation Medicine after Roche spent $2.4 billion on the testing company earlier this year on the conviction that future cancer treatment will more and more be tailored to individual characteristics of a person’s tumour.

From patients’ blood, Roche said Foundation’s test can identify circulating tumour DNA and identify 70 of the most commonly mutated genes in solid tumours, including features which may help identify patients most likely to benefit from cancer immunotherapy. (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below